SCHEMBL14601748

SCHEMBL14601748

CCCCCN(C)Cc1ccc(O)c(OC)c1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP2C8 P10632 1/20 0.53
CYP2B6 P20813 1/20 0.53
HTR1A P08908 1/20 0.53
DRD1 P21728 1/20 0.52
DRD3 P35462 1/20 0.52
SIGMAR1 Q99720 1/20 0.52
ALDH1A1 P00352 1/20 0.51
CYP2D6 P10635 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
BLM P54132 1/20 0.51
PMP22 Q01453 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952592 0.81 BCHE (0.44) CYP1A2CYP3A4CYP2C9SIGMAR1ALDH1A1
SCHEMBL11105252 0.80 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL11099994 0.80 CYP1A2 (0.51) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL11101082 0.80 CYP1A2 (0.57) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL9416630 0.79 TSHR (0.57) CYP1A2CYP3A4ALDH1A1ALOX15
SCHEMBL6566912 0.79 HTR1A (0.69) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL11648537 0.78 TAAR1 (0.61) CYP3A4ALDH1A1ALOX15
SCHEMBL7795393 0.78 CYP3A4 (0.64) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL16609989 0.77 HTR1A (0.72) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8
SCHEMBL9485313 0.77 HTR1A (0.72) CYP1A2CYP3A4CYP2C9CYP2C19CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007034329-A2 COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS EXONHIT THERAPEUTICS SA (FR) 2007-03-29 WO disclosed